

WEALTH WEEKLY

Weekly Alerts You Can Use!

Weekly View: Nifty, Bank Nifty:

Indices	CMP	Support	Resistance	50 DMA	200 DMA	Range	Preferred Trade
NIFTY	24565	23936	25000	25052	24050	24122-24822	Sell between 24677-24701. Targets at 24200/23936. Stop at 24901.
BANK NIFTY	55618	54200	56700	54623	52589	54300-56500	Sell at CMP. Targets at 54200/52900/52200. Stop 56800.

Medium Term Pick:

Stocks	CMP	Support	Resistance	50 DMA	200 DMA	Bias	Preferred Trade
AUROPHARMA	1080	1021	1173	1140	1201	Negative	<p>The stock at the moment is witnessing massive bearish breakdown on the daily and weekly charts and that's on backdrop of one way down move since September 2024.</p> <p>Major supports are now placed at 1010 (April 2025 low). The 200 DMA is placed at 1201 levels. The sequence of higher high/low is still intact on all time frames. Now below 1010-mark, momentum selling is quite likely.</p> <p>Preferred Strategy: Simply sell at CMP, and on strength between 1100-1115 zone, targeting 1010/975 mark and then at 901 mark. Stop above 1173. Holding Period: 1-3 Months.</p>

SELL AUROPHARMA CMP 1080, Targets 975

CMP	1080
Target Price	975
52 Week H/L	1592.55/994.35
P/E	35.9
EPS (TTM)	30.08
Promoter Holding/DIIs/FIIs	51.82/26.9/14.4
Book Value	353.55
Market Cap (INR)	62,709.15 crores

Daily Chart of AUROPHARMA :



Theme:

Founded in 1986, Aurobindo Pharma develops, manufactures, and commercializes a wide range of generic pharmaceuticals, active pharmaceutical ingredients (API) and injectables globally in over 150 countries.

Aurobindo Pharma leads the US generics market, generating \$3.5 billion in turnover in FY24. The company's US sales arm, Aurobindo Pharma USA Inc. (APUSA), distributes oral solid dosages and other products, ranking #1 by IMS for prescriptions in the US for Rx Generic Oral Solids (April 2024).

The negative takeaway is that India's unbranded generic pharma companies like Aurobindo Pharma are in the spotlight after the US President has said that tariffs on the sector are "coming soon."

Business Highlights – Q4FY25

- Highest ever quarterly revenues of ₹8,382 Crores with 5.1% growth QoQ
- Highest ever quarterly EBITDA with a good margin of 21.4%, driven by gross margins and operating efficiencies
- Net Capex of US\$ 90 million* primarily towards capacity enhancements, new business developments.
- Total R&D (incl. depreciation) spend for the quarter is ₹423 Crores
- Net cash including investments is at ~US\$ 42 million* as on Mar'25 against net debt of ~US\$84 million as on Dec'24

US market: Filed 9 ANDAs | Received approval for 5** products | Launched 5 products

Technical Outlook: The stock at the moment is witnessing massive bearish breakdown on the daily and weekly charts and that's on backdrop of one way down move since September 2024.

Major supports are now placed at 1010 (April 2025 low). The 200 DMA is placed at 1201 levels. The sequence of higher high/low is still intact on all time frames. Now below 1010-mark, momentum selling is quite likely.

Preferred Strategy: Simply sell at CMP, and on strength between 1100-1115 zone, targeting 1010/975 mark and then at 901 mark. Stop above 1173. Holding Period: 1-3 Months.

Mehta Equities

903 Lodha Supremus, Dr. E Moses Road, Worli Naka, Mumbai - 400 018 Board: +91-22-61507100/101 Fax: +91-22-61507102